Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P08908 (5-HT1A)
 5,574 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This study has examined the effects of 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), buspirone, nifedipine and verapamil on duration of immobility in the forced swimming test in mice. The 5-HT1A agonist-8-OH-DPAT (0.25, 0.5, 1 mg/kg) and dihydropyridine calcium channel antagonist-nifedipine (10 mg/kg) produced decreases in immobility time. These effects were similar to those of the tricyclic antidepressant-imipramine (5 and 10 mg/kg). Non-dihydropyridine calcium channel antagonist-verapamil (10 and 20 mg/kg) had no effect on immobility time. The non-benzodiazepine anxiolytic and 5-HT1A agonist-buspirone (1 mg/kg) when given in a single injection or as repeated treatment, did not exert antidepressant-like activity in the forced swimming test. Pretreatment with dopamine antagonist-haloperidol (0.5 mg/kg) significantly antagonized the effects of 8-OH-DPAT (1 mg/kg), imipramine (10 mg/kg) and nifedipine (10 mg/kg). Pretreatment with benzodiazepine anxiolytic-diazepam (2 mg/kg) antagonized the effect of imipramine (10 mg/kg) but not that of 8-OH-DPAT (1 mg/kg) or nifedipine (10 mg/kg). Neither haloperidol nor diazepam produced any effects in this test. Single or repeated administration of buspirone (1 mg/kg) did not alter the reduction of immobility time produced by imipramine (10 mg/kg). These results suggest that 5-HT1A agonists and dihydropyridine calcium channel blockers may have antidepressant efficacy in the forced swimming test, but the effects of buspirone and 8-OH-DPAT may be mediated via different mechanisms. These results also indicate that the relationship between serotonin and dopamine neurons may play a role in the action of antidepressant drugs. In addition, the interactions involving both GABAergic and serotoninergic processes exist between benzodiazepine anxiolytics and some antidepressants.
Pol J Pharmacol
PMID:Antidepressant-like properties of some serotonin receptor ligands and calcium channel antagonists measured with the forced swimming test in mice. 979 63

A number of new 1-phenyl- (a), 1-(3-chlorophenyl)- (b) and 1-(2-methoxyphenyl)- (c) piperazine derivatives containing 1,4-benzoxazin-3(4H)-one (2-4), 2,4-benzoxazin-3-(4H)-one (5), 1,2-benzoxazolin-3-one (6) and 1,3-benzoxazolin-2,4-dione (7) were synthesized. Radioligand binding measurements showed that the majority of compounds had a distinct affinity for 5-HT1A (3a, 6a, 2-5b, 6c; Ki = 7.5-81 nM) and/or 5-HT2A (2b, 5-7a,b; Ki = 18-69 nM) receptors. Structure-Activity Relationship (SAR) studies revealed structural features which seem to favour the binding to either or both of these two receptor subtypes. For evaluation of the functional in vivo profile of the most potent 5-HT1A (5b, 6b) and/or 5-HT2A (5-7b) ligands, the following tests were used: the 8-OH-DPAT-induced lower lip retraction (LLR) and behavioral syndrome in rats--for 5-HT1A receptor antagonistic activity, and the (+/-)DOI-induced head twitches in mice and the (+/-)DOI-induced discriminative stimulus properties in rats--for 5-HT2A receptor antagonistic properties. The obtained results show that compounds 5b and 6c behave like potent 5-HT1A antagonists, whereas 5b, 6b and 7b demonstrate 5-HT2A receptor antagonistic properties. None of the in vivo tested compounds, given alone, mimicked 8-OH-DPAT activity in those tests. It seems that derivative 5b, which has an equipotent 5-HT1A and 5-HT2A affinity and antagonistic properties at both these receptors, is a promising potential psychotropic substance.
Pol J Pharmacol
PMID:1,4-Benzoxazin-3(4H)-one derivatives and related compounds as 5-HT1A and 5-HT2A receptor ligands; the effect of the terminal amide fragment on the 5-HT1A/5-HT2A affinity and functional activity. 1009 18

A new series of arylpiperazines with two (2a-4a) and four (2c-4c) methylene spacers was synthesized. Compounds 2a, 2c, 3c, 4a and 4c were found to be 5-HT1A ligands (Ki = 4-88 nM). The most promising compound, 2c, bound with the highest affinity (Ki = 4 nM) at 5-HT1A sites. The results of in vivo experiments showed that compounds 2a-4a were inactive, while 2c-4c revealed a distinct antagonistic activity towards postsynaptic 5-HT1A receptors. The pharmacological profile of the tested compounds was discussed in comparison with that of the three methylene analogs b, described earlier.
Pol J Pharmacol
PMID:Effect of linking bridge modifications on the 5-HT1A receptor activity of some 4-(omega-benzotriazol-1-yl)alkyl-1-(2-methoxy-phenyl)piperazines. 1009 19

Three series of new 9-substituted 1,2,3,4-tetrahydro-beta-carbolin-1-ones with 2-, 3- and 4-membered alkyl chain (1, 2 and 3, respectively) were synthesized, and the effect of some structural modifications on their 5-HT1A and 5-HT2A receptor affinities and functional in vivo properties was discussed. Radioligand binding measurements showed that the majority of compounds had a distinct affinity for 5-HT1A (1b, 2a, 2b, 2c, 3b; Ki = 0.3-64 nM) and 5-HT2A receptors (1b, 2b, 2c, 3b; Ki = 0.9-80 nM). The most potent 5-HT1A (1b, 2a, 2b, 3b) and 5-HT2A (1b, 2b, 3b) ligands were evaluated in in vivo tests. The obtained results indicate that 1,2,3,4-tetrahydro-beta-carbolin-1-ones containing 1-(o-methoxyphenyl)piperazine (1-3b) show pharmacological profile of 5-HT1A postsynaptic antagonists (with very weak agonistic component) and 5-HT2A antagonists, compound with 1,2,3,4-tetrahydroisoquinoline (2a) is a pure 5-HT1A postsynaptic antagonist. Summing up, the connection of 1,2,3,4-tetrahydro-beta-carbolin-1-one moiety through the 2-4-membered alkyl spacer with 1-(o-methoxyphenyl)-piperazine, which is present in a variety of 5-HT1A ligands, allowed us to obtain the compounds with high and equal affinity for 5-HT1A/5-HT2A receptors and the expected functional properties, i.e. distinct antagonistic and weak agonistic activity at 5-HT1A postsynaptic receptors and antagonistic at 5-HT2A ones.
Pol J Pharmacol
PMID:9-substituted 1,2,3,4-tetrahydro-beta-carbolin-1-ones, new 5-HT1A and 5-HT2A receptor ligands. 1054 Sep 67

Two new analogs of full 5-HT1A receptor antagonist 4-[3-(1-benzotriazolyl)propyl]-1-(2-methoxyphenyl)piperazine (MP 3022; 1) containing di- (5) or tetramethylene- (6) spacer were synthesized. In the radioligand binding studies, compounds 5 and 6 showed high 5-HT1A (Ki = 14.7 nM and 11.8 nM, respectively) and low 5-HT2 receptor affinity (Ki = 2,696 nM and 389.2 nM, respectively). In behavioral studies both compounds behaved like postsynaptic 5-HT1A receptor antagonists as they reduced lower lip retraction and behavioral syndrome induced by 8-OH-DPAT (5-HT1A receptor agonist) in rats, but 6 was more effective in these tests. Derivative 5 did not affect body temperature in mice, whereas 6 decreased it. Furthermore, 5 did not change hypothermia induced by 8-OH-DPAT, and 6-induced lowering of body temperature in mice was not antagonized by (S)-WAY 100135 (5-HT1A antagonist), so in that model 5 and 6 did not behave as antagonist or agonist, respectively, at presynaptic 5-HT1A receptors. Compound 6 was studied in behavioral tests used to predict a potential anxiolytic (conflict drinking test in rats) and antidepressant (forced swimming test in rats) activity. Diazepam and imipramine were used as reference drugs. Compound 6 significantly increased the number of shocks accepted in water-deprived rats in conflict drinking test and shortened the immobility time in forced swimming test in rats. The above findings indicate that new 5-HT1A postsynaptic antagonist 6 behaves like anxiolytic and antidepressant, but mechanisms of these properties of 6 remain unknown.
Pol J Pharmacol
PMID:Some pharmacological properties of new analogs of MP 3022, the 5-HT1A receptor antagonist. 1081 41

A new set (3-11) of analogs of MP 3022 (1) containing the amide bond inserted into the intermediate chain linking the terminal heteroaromatic and 1-(2-methoxyphenyl)piperazine moieties were prepared and their 5-HT1A and 5-HT2A receptor affinities were determined. Only compounds with trimethylene chain between amide and arylpiperazine fragments (5a, 5b, 7a, 7b and 11) showed satisfactory affinity for 5-HT1A receptor (Ki = 42-87 nM) and high 5-HT2A/5-HT1A selectivity. The new 5-HT1A receptor ligands were investigated in vivo to determine their 5-HT1A agonistic or antagonistic properties. Compounds 7a and 7b with terminal indazole fragment as well as 11 with phenyl substituent behaved like weak 5-HT1A receptor antagonists. The structure-affinity relationship studies in this series of compounds revealed that the amide group along with the terminal aromatic fragments contributed to interaction with 5-HT1A receptor sites, whereas in vivo results indicated that introduction of the amide group into presented arylpiperazine structures was not a profitable modification for their 5-HT1A functional activity.
Pol J Pharmacol
PMID:Effect of the amide fragment on 5-HT1A receptor activity of some analogs of MP 3022. 1081 42

Novel arylpiperazines (1a, 1c, 2a and 2c), containing a terminal 1- or 2-indazolyl fragment and a di- or tetramethylene aliphatic spacer, were synthesized and their 5-HT1A and 5-HT2A receptor affinities were determined. All those compounds showed a potent affinity for 5-HT1A receptors (Ki = 5-16 nM) and were evaluated for an intrinsic activity at those receptors. In order to determine a 5-HT1A agonistic effect of the investigated compounds, their ability to induce a lower lip retraction in rats and a behavioral syndrome (flat body posture and forepaw treading) in reserpinized rats were tested, whereas their 5-HT1A antagonistic activity was assessed via inhibition of those symptoms produced by 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT). The effect of spacer length on the 5-HT1A activity of the tested compounds was discussed in comparison with that of the three-methylene analogs (1b and 2b) described earlier. Both dimethylene derivatives (la and 2a) were characterized as weak postsynaptic 5-HT1A receptor antagonists. Compounds 1c (1-indazolyl analog) and 2c (2-indazolyl analog) with a tetramethylene aliphatic chain were classified as a postsynaptic 5-HT1A antagonist and a partial 5-HT1A agonist, respectively. Furthermore, the latter showed a moderate anxiolytic-like effect (conflict drinking Vogel's test in rats) and a weak antidepressant-like activity (forced swimming Porsolt's test in rats).
Pol J Pharmacol
PMID:Influence of the aliphatic spacer length on the 5-HT1A receptor activity of new arylpiperazines with an indazole system. 1105 78

Many studies of schizophrenic brains indicate the dysfunction of dopamine and glutamate systems in the prefrontal and frontal cortex. It seems that better understanding of mechanisms regulating functions of these neuronal cortical systems could contribute to creation of new drugs acting in the cortex selectively. This might be profitable in cognition of dysfunction and negative symptoms in schizophrenia. This article presents preclinical data concerning the role of 5-HT1A serotonin receptors in the modulation of cortical dopamine system and in psychotomimetic effects of non-competitive NMDA receptor antagonists. Neurochemical studies have shown that 5-HT1A receptor agonists increase dopamine release in the rat prefrontal cortex on the one hand, and they inhibit the augmentation of dopamine release induced by stress or amphetamine, on the other. However, the increase of dopamine release induced by non-competitive NMDA receptor antagonists is blocked by 5-HT1A receptor antagonists. Blockade of 5-HT1A receptors seems to be important also in reduction of most psychotomimetic effects induced by non-competitive NMDA antagonists both involving (locomotor hyperactivity, working memory impair) and not involving (sensorimotor gating deficits) dopamine mechanism. Thus, binding with 5-HT1A receptors can be an important site for the regulation of cortical dopamine system, both in physiological conditions and in disregulation of the system induced by stress, psychostimulants or psychotomimetics. On the other hand, 5-HT1A receptors modulate most of psychotomimetic effects of non-competitive NMDA receptor antagonists. The above results of preclinical investigations indicate that 5-HT1A receptor can be involved in the pathology of schizophrenia, what is partly confirmed by clinical postmortem studies of schizophrenic brains. These studies showed the increase of 5-HT1A receptor density in prefrontal and frontal cortex in schizophrenic brains. It also seems that 5-HT1A receptors might be a good target for the antipsychotic drugs. Although the clinical studies have demonstrated controversial data, maybe further studies using substances with selectivity to 5-HT1A receptors would help to determine more precisely the role of these receptors in pathology and pharmacotherapy of schizophrenia.
Psychiatr Pol
PMID:[The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia]. 1105 60

In present study the structure-selectivity relationship of buspirone and six of its analogues towards 5-HT1A and 5-HT2A serotonin receptors was investigated on molecular level. Molecular mechanics energy minimisation and advanced molecular dynamics (MD) simulations allowed us to perform a dynamic structural analysis of transmembrane helical domains of the human 5-HT1A and 5-HT2A receptors and investigate the ligand-induced changes of the entire structure of the ligand-receptor complex. The obtained results suggest, that helical and extracellular domains of both receptors have different topography of the putative binding sites and also different dynamical behaviour. The results of this study are consistent with experimental site-directed mutagenesis data and binding affinities of examined ligands towards both serotonin receptors.
Acta Pol Pharm 2000 Nov
PMID:Theoretical models of interactions between buspirone analogues and 5-HT1A and 5-HT2A serotonin receptor subtypes. 1129 60

The effects of selective manipulations of activity of the serotonergic and noradrenergic systems were examined in the rat model of visceral pain. It was found that neither p-chlorophenylalanine(p-CPA)- nor N-chloro-ethyl-2,2--bromo-benzylamine(DSP-4)-induced strong and selective depletion of the brain and spinal cord serotonin and noradrenaline, respectively, changed in a significant way rat visceral pain perception. On the other hand, 8-OH-DPAT, a full selective 5-HT1A receptor agonist, prazosin, an alpha1-adrenoceptor antagonist, clonidine, an alpha2-adrenoceptor agonist, and two beta-adrenoceptor antagonists: propranolol and metoprolol, dose-dependently reduced the number of body writhes induced by intraperitoneally administered 2% solution of acetic acid (the writhing test). The results obtained with selective receptor ligands, DSP-4 and p-CPA, indicate that the noradrenergic and serotonergic innervation of the central nervous system contribute in a complex way to the animal behavior in the writhing test. The 5-HT1A receptors and alpha2-adrenoceptors play an inhibitory role in the expression of rat behavior in this model of visceral pain. On the other hand, adrenergic alpha1 and beta1 receptors facilitate the behavioral effects of the irritant agent.
Pol J Pharmacol
PMID:Role of serotonergic and noradrenergic systems in a model of visceral pain. 1199 65


<< Previous 1 2 3 4 5 6 Next >>